Tahoora Mousavi

Dr. Tahoora Mousavi


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MGMonireh Golpour
Monireh Golpour
HJHossein Jalali
Hossein Jalali
RAReza Alizadeh-Navaei
Reza Alizadeh-Navaei
MTMasoumeh Rezaei Talarposhti
Masoumeh Rezaei Talarposhti
TMTahoora Mousavi
Tahoora Mousavi
AGAli Asghar Nadi Ghara
Ali Asghar Nadi Ghara
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) is a public health problem and may result in co-infection with other pathogens such as influenza virus. This review investigates the co-infection of SARS-CoV-2 and influenza A/B among patients with COVID-19. This meta- analysis included 38 primary studies investigating co-infection of SARS-CoV-2 with influenza in confirmed cases of COVID-19. The global online databases were used to identify relevant studies published between December 2019 and July 2024. Data analysis was performed using STATA Ver. 17 software, and standard errors of prevalence were calculated using the binomial distribution formula. Heterogeneity of study results was evaluated using the I-square and Q index, and publication bias was examined using the Begg’s and Egger’s tests, as well as funnel plot. A random effects model was used to determine prevalence rates, and a forest plot diagram was used to present results with 95% confidence intervals. In addition, sensitivity analyses were performed to check the impact of each primary study on the overall estimate. The analysis found that the prevalence of influenza in co-infected patients at 95% confidence interval using a random effect model was 14% (95% CI: 8–20%). Significant heterogeneity was observed in the random-effects model for influenza A, 11% (95% CI: 5-18%) and B, 4% (95% CI: 2-7%) in co-infected patients. The highest prevalence of influenza A/B (21%), influenza A (17%) and influenza B (20%) was shown in Asia and Europe respectively. Subgroup analysis by study year showed that the co-prevalence of COVID-19 and influenza A/B was similar in the pre-2021 and post-2021 time periods, at 14% (95% CI: 5-23%) for pre-2021 and 6-22% for 2021 and post-2021. Also, the overall prevalence of influenza A and B in COVID-19 patients is 11% and 4%, and there was no significant difference between the time periods before and after 2021. Meta-regression with a random-effects model showed that the variables location, year group, and total patients showed only 2.71% of very high heterogeneity (I² = 99.92%), and none of these variables had a significant effect on the co-prevalence of COVID-19 and influenza A/B (p > 0.05). Also, meta-regression results showed that these variables had no significant effect on influenza A and B prevalence (p > 0.05) and showed only a small proportion of the very high heterogeneity (I² = 99.72%), (I² = 68.78%). In our study, Egger’s test indicated that there was publication bias or small study effects in this meta-analysis (p = 0.0000). The combination of SARS-CoV-2 with influenza and other respiratory viruses requires the best treatment protocols to reduce the severity of the disease. In this approach, high vaccination coverage against seasonal influenza and SARS-CoV-2 could reduce the risk of co-infection in the recent pandemic.

24 January 2024 in Inorganic Chemistry Communications
Verified
Journal Article
Closed access
MGMonireh Golpour
Monireh Golpour
PEPedram Ebrahimnejad
Pedram Ebrahimnejad
ZGZahra Rezanejad Gatabi
Zahra Rezanejad Gatabi
ANAhmad Najafi
Ahmad Najafi
ADAli Davoodi
Ali Davoodi
TMTahoora Mousavi
Tahoora Mousavi

7 December 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
MMMahmood Moosazadeh
Mahmood Moosazadeh
TMTahoora Mousavi
Tahoora Mousavi
The coagulation markers, pro‐inflammatory cytokines (such as IL‐2R, IL‐6, IL‐10, and TNF‐a) and lymphopenia are associated with the severity of coronavirus disease 2019 (COVID‐19) disease. The use of anti‐inflammatory agents, such as corticosteroids (CS) or tosilizumab (TCZ), has been suggested for the treatment of advanced stage of COVID‐19 and the reduction of mechanical ventilators and mortality. The aim of this meta‐analysis is to determine the role of combination therapy with tocilizumab and steroids in COVID‐19 patients. Relevant studies were found using online international databases, and suitable studies were selected and assessed by two independent researchers. The quality of all papers was determined by a checklist. Heterogeneity assay among the primary studies was evaluated by Cochran's Q‐test and I2 index. The statistical analyses were done using the Stata ver. 14 package (StataCorp) software. Publication bias was estimated through Egger's test, and the impact of each study on the overall estimate was assessed by sensitivity analysis. Five studies were entered into this meta‐analysis. The results of these studies showed that the risk of death for COVID‐19 patients treated with the combination of corticosteroids and tocilizumab compared to tocilizumab and the control group was 0.74 (95% confidence interval [CI]: 0.36–1.50) and 0.48 (95% CI: 0.31–0.74), respectively. This meta‐analysis showed that the risk of death in COVID‐19 patients who were treated with corticosteroids and tocilizumab was lower than the tocilizumab alone and control groups (26% and 52%, respectively).

6 June 2018 in Experimental and Therapeutic Medicine
Verified
Journal Article
Closed access
PDF file
LDLotfollah Davoodi
Lotfollah Davoodi
BMBabak Masoum
Babak Masoum
MMMahmood Moosazadeh
Mahmood Moosazadeh
HJHamed Jafarpour
Hamed Jafarpour
MHMohammad Reza Haghshenas
Mohammad Reza Haghshenas
TMTahoora Mousavi
Tahoora Mousavi
An estimated 185 million people worldwide are infected with hepatitis C virus (HCV). Combination therapy with pegylated interferon‑α (peg IFN) and ribavirin is the first line of treatment against the psychiatric side effects, including mood disorders, anxiety and irritability. In the present study, all of the studies electronically published between 2000 and 2016 were retrieved using databases including Scopus, PubMed, Institute for Scientific Information, Science Direct and Google Scholar. All of the articles were independently evaluated by two reviewers and the results were compared, followed by removal of duplicate, irrelevant and re‑published studies after reviewing. The studies were assessed based on the heterogeneity of their results using the Cochrane test and I2 analysis. All groups included neuropsychiatric side effects, fatigue was reported at the highest rate in 60.41% [95% confidence interval (CI)=39.18‑81.64%] and insomnia was reported at a lower rate in 16.28% of cases (95% CI=6.59‑25.98%). In conclusion, the present meta‑analysis indicated that treatment with peg IFN + ribavirin or interferon only is associated with a wide range of neuropsychiatric side effects, including fatigue, mood disorders, anxiety, irritability, emotional ability and agitation.

2 November 2022 in Transplant Immunology
Verified
Journal Article
Closed access
MAMina Alimohammadi
Mina Alimohammadi
MMMahmood Moosazadeh
Mahmood Moosazadeh
AMAlireza Mardomi
Alireza Mardomi
TMTahoora Mousavi
Tahoora Mousavi

4 December 2019 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
TMTahoora Mousavi
Tahoora Mousavi
SSSogol Sattari Saravi
Sogol Sattari Saravi
RVReza Valadan
Reza Valadan
MHMohammad Reza Haghshenas
Mohammad Reza Haghshenas
ARAlireza Rafiei
Alireza Rafiei
ASAmir Shamshirian
Amir Shamshirian